Citations

Clear

6729 citation(s) found for "Li, Mark".

Presacral tumours: international consensus on diagnosis and management
Perry, William R G, Brown, KF, Burns, Elaine, Frizelle, Frank, Glover, Thomas , Glyn, Tamara , Heriot, Alexander, Merchea, Amit , Quyn, Aaron, Sagar, P., Thomas, Gregory, Tiernan, Jim , Turner, Gregory A., Warrier, Satish, Wood, Verity, Group, the Presacral Tumour Working, Cerkaukaite, Dovile, Khan, Ayman , Koneru, S R, Vu, J, Jenkins, John T. , Dozois, E, Heriot, Alexander G. , Perry, William , Perry, William R , Heriot, Alexander , Merchea, Amit , Sagar, Peter , Solomon, Michael J , Burns, Elaine Marie , Denost, Quentin , Graham, Rondell P. , Solomon, Michael J. , Turner, Gregory A, Wood, Verity , Koneru, Sireesha, Litchinko, Alexis , Dozois, Eric J.

Mayo Clinic

British Journal of Surgery | April 28, 2026 | Volume: 113 | Issue: 5 | Pages: No page available

10.1093/bjs/znag053 | PMID 42049258 Get It

Abstract Background Presacral tumours are rare and heterogeneous lesions arising within a complex anatomical space, resulting in variability in diagnosis and management. Increasing incidental detection and evolving surgical and oncological strategies have highlighted the need for contemporary guidance. The aim of this study was to establish an international expert consensus on the optimal diagnosis and management of presacral tumours. Methods An international panel of colorectal surgeons from high-volume units was convened. Evidence- and practice-based statements were developed after domain-based literature reviews and refined through five online and two in-person meetings. Consensus was achieved using a modified Delphi process with anonymous voting. Results In total, 16 colorectal surgeons participated in the study. Ten domains were identified resulting in the development of 22 statements based on expert opinion and retrospective studies. After two rounds, unanimous (100%) agreement was achieved for all statements. High-resolution MRI with structured synoptic reporting is endorsed as central to risk stratification. Selective image-guided transperineal or parasacral biopsy is recommended for high-risk lesions where histology would alter management. Complete surgical resection is defined as the operative goal, with approach tailored to tumour biology and anatomy; minimally invasive surgery is considered appropriate in selected cases. Non-operative surveillance is supported for carefully selected asymptomatic, low-risk cystic lesions. Postoperative surveillance is recommended in a risk-adapted manner according to histopathology and margin status. Conclusion This international consensus provides a pragmatic, risk-stratified framework for the multidisciplinary diagnosis and management of presacral tumours. These recommendations aim to reduce practice variation, support decision-making in specialized centres, and inform future prospective collaborative research.
Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Meletti, Stefano, Hanin, Aurelie, Bedin, Roberta , Burani, Margherita , Taruffi, Lisa , Urbano, Teresa, d’Achille, Fabio, Malerba, Mara, Basha, Maysaa M., Eschbach, Krista, Farias-Moeller, Raquel, Gerard, Elisabeth E., Gofton, Teneille, Gopaul, Margaret T., Haider, Hiba A. , Hantus, Stephen , Herman, Susan, Kang, Peter, Kandula, Padmaja , Taraschenko, Olga , Wainwright, Mark, Zhou, Daniel J., Lattanzi, Simona, Navarro, Vincent, Hirsch, Lawrence J., Meletti, Stefano , Haider, Hiba A , Hanin, Aurélie , Giovannini, Giada , Orlandi, Niccolò , Urbano, Teresa , Malerba, Mara, Basha, Maysaa , Foreman, Brandon , Farias‐Moeller, Raquel , Gaspard, Nicolas , Gofton, Teneille , Gopaul, Margaret , Day, Gregory S. , Steriade, Claude , Struck, Aaron F. , Wainwright, Mark S. , Yoo, Ji Yeoun , Lattanzi, Simona , Navarro, Vincent , Hirsch, Lawrence J.

Mayo Clinic

JAMA Neurology | April 27, 2026 | Volume: 83 | Issue: 6 | Pages: 563

10.1001/jamaneurol.2026.0865 | PMID 42043830 Get It

Importance Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. Design, Setting, and Participants This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. Exposures Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). Main Outcomes and Measures Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. Results A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE—approximately 10-fold higher in CSF and 4-fold higher in serum—compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset ( P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). Conclusions and Relevance Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
Silvey, Scott , Choudhury, Ashok , Kamath, Patrick S. , Wong, Florence , Hayes, P C, Seto, Wai‐Kay , Singhal, Garima, Jothimani, Dinesh , Asrani, Sumeet, Gadano, Adrián , Dinçer, Dinc , Adebayo, Daneille, Doyle, Adam, Debzi, Nabil , Shaw, Jawaid , Barutçu, Sezgin , Lah, Ponan Claude Regis, Duarte‐Rojo, Andrés , Turan, Dilara , Wang, Lei, Velazquez, René Malé, Aghayaeva, Sevda, Córdova-Gallardo, J, Xu, Bin, Gao, Haibing , Elangovan, Harendran, Fung, James, Rajorya, Neil, Wang, X I A O Y U, Katchman, Helena , Jiang, Yongfang, Thanapirom, Kessarin , Eapen, CE, Dhiman, Radha K. , Lu, Mingqin, Su, Minghua , Hueso, Sarai Gonzalez, Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping, MacQuillan, Gerry, Pereira, Gustavo, Reddy, K. Rajender , Topazian, Mark, Torre, A Ullate De La, Silva, Mario, Bush, Brian J., Bajaj, Jasmohan S. , Chaudhary, Ashok , Xie, Qing , Wong, Florence , Arora, Umang , Gadano, Adrian , Dincer, Dinc , Velarde-Ruiz Velasco, José Antonio , Kulkarni, Anand V , Shaw, Jawaid , Desalgn, Hailemicheal , Bettinger, Dominik , Regis Lah, Ponan Claude , Duarte-Rojo, Andres , Turan, Dilara , Zheng, Xin , Demirtas, Coskun , Liu, Chenghai , Cordova-Gallardo, Jacqueline , Nagral, Aabha , Gao, Haibing , Katchmann, Helena , Praharaj, Dibyalochan , Mahadeva, Sanjiv , Eapen, C E , Dhiman, Radha K , Lu, Mingqin , Arrese, Marco , Su, Minghua , Hueso, Sarai Gonzalez , Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping , Taneja, Sunil , Sonavane, Amey , Saraya, Anoop , Gofton, Cameron , Pereira, Gustavo , Rajender Reddy, K , Sarin, Shiv Kumar , Cao, Zhujun , Topazian, Mark D , Idilman, Ramazan , Torre, Aldo , George, Jacob , BUSH, BRIAN J. , Bajaj, Jasmohan S , Seto, Wai-Kay , Singhal, Garima, Asrani, Sumeet K. , Farias, Alberto Queiróz , Velasco, J.A. Velarde-Ruiz , Kulkarni, Anand V. , Desalegn, Hailemichael , Karasu, Zeki A. , Fung, James , Rajoriya, Neil , Zheng, Katina , Arrese, Marco , Zhu, Chuanwu , Taneja, Sunil , Aravinthan, Aloysious Dominic , MacQuillan, Gerry C., Idılman, Ramazan , George, Jacob , Alvares-da-Silva, Mario Reis

Mayo Clinic

American Journal of Gastroenterology | April 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004031 | PMID 42043180 Get It

INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C
Hiwot, Tarekegn , Porter, Forbes D. , Ramaswami, U, Hastings, Caroline, Héron, Bénédicte, Hopkin, Justin, Melville, Joella, Amartino, Hernán, Ezgü, Fatih, Gissen, Paul, Gibson, James B., Giugliani, Roberto, Staretz‐Chacham, Orna, Platt, Frances, Guffon, Nathalie , Julich, Kristina, Lehman, Anna, Nadjar, Yann , Schneider, Susanne A., Jones, Simon, Mengel, Eugen , Tchan, Michel , Göker-Alpan, Özlem , Dawson, Charlotte, Cowie, Sandra, Mathieson, Toni, Berry‐Kravis, Elizabeth, Gissen, Paul , Platt, Frances M. , Geberhiwot, Tarekegn , Ramaswami, Uma , Ramaswami, Uma , Hastings, Caroline , Deodato, Federica , Julich, Kristina , Nadjar, Yann , Goker-Alpan, Ozlem , Mathieson, Toni , Patterson, Marc C. , Gissen, Paul , Hiwot, Tarekegn, Bremova-Ertl, Tatiana , Héron, Bénédicte , Hopkin, Justin, Amartino, Hernán , Toro, Mireia del , Ezgü, Fatih Süheyl , Ficicioglu, Can H. , Giugliani, Roberto , Staretz‐Chacham, Orna , Kresojević, Nikola D. , Lehman, Anna , Schneider, Susanne A. , Jones, Simon, Walterfang, Mark , Dawson, Charlotte , Berry‐Kravis, Elizabeth

Mayo Clinic

Journal of Inherited Metabolic Disease | April 27, 2026 | Volume: 49 | Issue: 3 | Pages: No page available

10.1002/jimd.70185 | PMID 42036217 Get It

ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal disorder. Since then, advances in diagnostics, care, and the approval of two novel disease‐modifying agents have underscored the need to revise these guidelines to ensure safe, consistent, and high‐quality care for those affected by NPC. In response, the INPDA and INPDR convened a multidisciplinary Guidelines Development Group (GDG) comprising individuals with NPC expertise from 14 countries across five continents, representing a broad range of specialties, as well as patients and families involved in NPC care. Informed by a comprehensive literature review and two meetings, the GDG systematically reviewed, revised, and updated the 2018 guideline statements, re‐evaluating the level of evidence, strength of recommendations, and expert agreement for each. The resulting 2025 consensus clinical management guidelines constitute a timely, up‐to‐date, and internationally applicable resource for the diagnosis, treatment, and holistic management of individuals with NPC. These guidelines serve as a critical resource for specialist centers, hospital‐based medical teams, staff involved in NPC patient care, family physicians and other primary caregivers, and, importantly, patients and their families.
Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling
Mercer, Thomas J., Dániel, Bence , Fredrickson, Craig, Le, Daniel , Lee, Serena, Kulkarni, Vineet Vinay , Hou, Xu , Ngu, Hai , Jung, Min, Heon‐Roberts, Rachel , Smith, Amelia, Cheung, Tommy K. , Gastaldo, Denise , Jeong, Claire G. , Foreman, Oded , Bingöl, Bariş , Fiesel, Fabienne C , Ryan, Brent J , Dickson, Dennis W , Fiesel, Fabienne C. , Kameswaran, Vasumathi , Dickson, Dennis W. , Springer, Wolfdieter , Rose, Christopher M.

Mayo Clinic

No container title available | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.24.719390 | PMID 42079170 Get It

Abstract Parkinson’s disease (PD) is commonly associated with dysfunctional mitochondrial homeostasis. PINK1, a S/T kinase mutated in early-onset PD, generates phosphoserine 65 ubiquitin (pS65Ub) on damaged mitochondria facilitating their removal. Here, we show that pS65Ub translocates into the nucleus after generation at damaged mitochondria and is directly attached to substrates by resident E3 ligases. Histone H2A is a major substrate and is modified at lysine 119 (H2AK119) by the polycomb silencer, E3 ligase RING1B. At nucleosomes, pS65Ub simultaneously suppresses RING1B and potentiates H2A deubiquitinases USP16 and USP21. Epigenetic profiling and RNA sequencing reveal that pS65Ub is enriched at the promoters of poorly expressed yet dynamically regulated genes and is associated with H2AK119ub depletion. Functionally, we show that pS65Ub enrichment drives polycomb target gene expression, which accelerates the maturation of dopaminergic neurons. Importantly, post-mortem PD brains exhibit elevated nuclear pS65Ub, potentially linking nuclear pS65Ub accumulation with disease pathogenesis. Together, these data indicate that pS65Ub generated at damaged mitochondria regulates fundamental cellular processes at distant sites.
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
The Impact of Endoscopic Ultrasound and Multidisciplinary Team Evaluation on the Management of Pancreatic Cystic Lesions
Altayar, Osama , Hoegger, Mark J. , Chu, Linda, Zaheer, Atif , Zandieh, Ghazal , Kushnir, Vladimir , Lang, Gabriel , Goggins, Michael, Hawkins, William, Khan, Adeel , Burns, William, Lafaro, Kelly, Lim, Kian‐Huat, Pederson, Katrina, Das, Koushik K. , Altayar, Osama , Genere, Juan Reyes , Khan, Adeel , Das, Koushik , Dbouk, Mohamad H. , Genere, Juan Reyes , Rengarajan, Arvind , Mellnick, Vincent M. , Shetty, Anup S. , Goggins, Michael , Lafaro, Kelly J. , Lim, Kian-Huat , Afghani, Elham

Mayo Clinic

United European Gastroenterology Journal | April 23, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/ueg2.70212 | PMID 42023483 Get It

ABSTRACT Background Retrospective evaluations of multidisciplinary team (MDT) review of pancreatic cystic lesions (PCL) demonstrate improved PCL management. Endoscopic ultrasound (EUS) evaluates PCL for worrisome features; however, its influence on MDT is unclear and may be attenuated by anchoring/confirmation bias. We aimed to evaluate the impact of EUS and the overall performance of MDT evaluation of PCL. Methods Four mock MDT sessions at two institutions were presented imaging from 40 consecutive PCL cases (20 “high‐risk” with advanced neoplasia, 20 “low‐risk” with pathologic low‐grade dysplasia or ≥ 3 years of non‐progression on surveillance), with and without upfront EUS/FNA (cytology, CEA, Amylase), in a randomized, crossover design. Group 1 adjudicated without EUS, Group 2 adjudicated with EUS, and Group 3 adjudicated with EUS after initially adjudicating without it. Results The cohort included branch‐duct ( n = 20), mixed type ( n = 6), and main duct ( n = 4) IPMN, MCN ( n = 5), and non‐mucinous PCL ( n = 5). Group 2 (EUS) correctly identified mucinous PCL with 97% sensitivity and 70% specificity, significantly higher than Group 1 (No EUS) (Sensitivity 91%, Specificity 20%; p = 0.04). Group 3 (Unblinded to EUS) performed significantly worse in mucinous PCL identification compared with Group 2, indicating cognitive bias (Sensitivity 97%, Specificity 10% ( p = 0.0003)). Group 2 correctly identified high‐risk PCL that required surgical intervention with 85% sensitivity and 85% specificity, significantly higher than Group 1 (Sensitivity 60%, Specificity 75%; p = 0.0016) and Group 3 (Sensitivity 73%, Specificity 80%, p = 0.0485). Conclusion While susceptible to cognitive bias, EUS significantly improves MDT assessment of PCL. MDT establishes a high bar for iterative additions of biomarkers to PCL analysis.
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imag
Sharpton, Suzanne R. , Diaz, Luis Antonio, Pepin, Kay , Amangurbanova, Maral , Madamba, Egbert , Bettencourt, Ricki , Singh, Seema, Dalupang, Mary, Tesfai, Kaleb , Middleton, Michael S. , Behling, C, Nakajima, Atsushi , Imajo, Kento , Ogawa, Yuji, Halegoua‐DeMarzio, Dina, Huang, Daniel Q., Balakrishnan, Maya, Gray, Meagan , Rodriguez, Manuel, DeLeon, Andre, Puskoor, Rohit, Behari, Jaideep , Hansen, Lars, Miller, Cynthia, Medici, Valentina , Boursier, Jerome, Richards, Lisa, Díaz, Luis Antonio , Sharpton, Suzanne , Díaz, Luis A , Nakajima, Atsushi , Imajo, Kento , Huang, Daniel Q , Vuppalanchi, Raj , Medici, Valentina , Tincopa, Monica , Ehman, Richard , Singh, Seema, Valasek, Mark A. , Dunn, Winston , Caussy, Cyrielle , Mohanty, Arpan , Huang, Daniel Q. , Fuchs, Michael A. , Hameed, Bilal , Stine, Jonathan G. , Balakrishnan, Maya , Vuppalanchi, Raj , Sarkar, Souvik , Boursier, Jerome, Tincopa, Monica A. , Ajmera, Veeral , Sirlin, Claude B. , Ehman, Richard L. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 22, 2026 | Volume: 64 | Issue: 3 | Pages: 334-344

10.1111/apt.70696 | PMID 42017265 Get It

ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver‐related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non‐invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver‐related outcomes. Aims To describe the design and rationale of the GOLDMINE study, established to determine whether non‐invasive imaging biomarkers predict MASLD progression and liver‐related clinical outcomes. Methods GOLDMINE is an investigator‐initiated, multi‐centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy‐proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration‐controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton‐density‐fat‐fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2‐year intervals (years 2 and 4), with annual follow‐up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver‐related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all‐cause mortality, with independent central adjudication of all events. Conclusions GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI‐based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood‐based prognostic biomarkers in MASLD.
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention
Harrison, Theresa M., Harvey, Danielle J., Chadwick, Trevor, Chao, Yishu , Taggett, Jacinda , Maillard, Pauline, Lovato, Laura, Farias, Sarah, Papp, Kathryn V., Lockhart, Samuel N., Toga, Arthur W., Koeppe, Robert A., Jagust, William J., Whitmer, Rachel A., Snyder, Heather M. , Carrillo, Maria C., Baker, Laura D. , Espeland, Mark A., Vemuri, Prashanthi, DeCarli, Charles, Landau, Susan M., Harvey, Danielle , Carrillo, María C. , Harvey, Danielle J , Harrison, Theresa M. , Maillard, Pauline , Lovato, Laura, Farias, Sarah Tomaszewski , Papp, Kathryn V. , Lockhart, Samuel N. , Toga, Arthur W. , Koeppe, Robert A. , Jung, Youngkyoo , Jagust, William J. , Whitmer, Rachel A. , Espeland, Mark Andrew , Vemuri, Prashanthi , DeCarli, Charles , Landau, Susan

Mayo Clinic

JAMA Neurology | April 20, 2026 | Volume: 83 | Issue: 6 | Pages: 521

10.1001/jamaneurol.2026.0832 | PMID 42008251 Get It

Importance Brain imaging biomarkers may (1) identify underlying mechanisms of intervention effects and (2) define brain characteristics of those most likely to benefit cognitively from the intervention. Objective To test whether (1) a lifestyle intervention is related to brain changes, (2) brain changes are correlated with intervention-specific cognition changes, and (3) brain imaging biomarkers provide information about who is likely to benefit from a lifestyle intervention. Design, Setting, and Participants In this randomized clinical trial, the POINTER Imaging study was an ancillary study of the 2-year, single-blind multicenter US POINTER clinical trial in which neuroimaging data were collected on eligible enrolled participants. The study was conducted from May 2019 to March 2023 (final follow-up, May 14, 2025). Participants were enrolled into the POINTER Imaging study following a standard procedure at 5 clinical sites in the US. Participant eligibility criteria included an age of 60 to 79 years, sedentary lifestyle, and suboptimal diet, plus at least 2 additional risk criteria for cognitive decline and no contraindications for neuroimaging. Interventions Participants were randomly assigned to receive the structured or self-guided intervention. Both interventions emphasized increased physical and cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring, but they differed in intensity and accountability. Main Outcomes and Measures There were 4 primary imaging outcomes: global β-amyloid (Aβ) burden, tau burden in the entorhinal cortex (ERC), hippocampal (HC) volume, and white matter hyperintensity volume. The primary cognitive measure was a global cognitive composite. Results Among 1943 parent trial participants who were assessed for eligibility, 983 underwent at least 1 magnetic resonance imaging or positron emission tomography scanning session. The mean (SD) age was 68.4 (5.2) years; 605 participants (61.5%) were female and 378 male (38.5%). Five hundred sixteen participants received the structured intervention and 467 the self-guided intervention. There were no intervention group differences in longitudinal cognitive or imaging outcomes. Intervention group differences were not associated with or moderated by Aβ status or accumulation. There was a negative association between change in ERC tau and change in global cognition in the self-guided group that was attenuated in the structured group (difference in association: 0.289; 95% CI, 0.029 to 0.550; interaction P = .03). Lower baseline HC volume was associated with greater cognitive benefit for participants in the structured group vs the self-guided group (lower HC: 0.077 SD; 95% CI, 0.022 to 0.132; higher HC: 0.002 SD; 95% CI, −0.037 to 0.041; interaction P = .03). Conclusion and Relevance This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03688126